1 / 131

Clinical Epilepsy

Clinical Epilepsy. American Epilepsy Society. Definitions.  Seizure: the clinical manifestation of an abnormal, excessive excitation and synchronization of a population of cortical neurons  Epilepsy: two or more recurrent seizures unprovoked by systemic or acute neurologic insults.

holden
Download Presentation

Clinical Epilepsy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Clinical Epilepsy American Epilepsy Society

  2. Definitions  Seizure: the clinical manifestation of an abnormal, excessive excitation and synchronization of a population of cortical neurons  Epilepsy: two or more recurrent seizures unprovoked by systemic or acute neurologic insults

  3. Epidemiology of Seizures and Epilepsy  Seizures Incidence: 80/100,000 per year Lifetime incidence: 9% (1/3 febrile convulsions)  Epilepsy Incidence: 45/100,000 per year Point prevalence: 0.5-1% Cumulative lifetime incidence: 3%

  4. ILAE Classification of Seizures

  5. ILAE Classification of Seizures

  6. ILAE Classification of Seizures

  7. Complex Partial Seizures  Impaired consciousness  Clinical manifestations vary with site of origin and degree of spread • Presence and nature of aura • Automatisms • Other motor activity  Duration typically < 2 minutes

  8. Secondarily Generalized Seizures  Begins focally, with or without focal neurological symptoms  Variable symmetry, intensity, and duration of tonic (stiffening) and clonic (jerking) phases  Typical duration 1-3 minutes  Postictal confusion, somnolence, with or without transient focal deficit

  9. EEG: Partial Seizure Right temporal seizure with maximal phase reversal in the right sphenoidal electrode

  10. EEG: Partial Seizure Continuation of same seizure Right temporal seizure with maximal phase reversal in the right sphenoidal electrode

  11. ILAE Classification of Seizures

  12. Typical Absence Seizures  Brief staring spells (“petit mal”) with impairment of awareness • 3-20 seconds • Sudden onset and sudden resolution • Often provoked by hyperventilation • Onset typically between 4 and 14 years of age • Often resolve by 18 years of age  Normal development and intelligence  EEG: Generalized 3 Hz spike-wave discharges

  13. EEG: Typical Absence Seizure

  14. Atypical Absence Seizures  Brief staring spells with variably reduced responsiveness • 5-30 seconds • Gradual (seconds) onset and resolution • Generally not provoked by hyperventilation • Onset typically after 6 years of age  Often in children with global cognitive impairment  EEG: Generalized slow spike-wave complexes (<2.5 Hz)  Patients often also have Atonic and Tonic seizures

  15. Atypical Absence Seizures

  16. Myoclonic Seizures  Brief, shock-like jerk of a muscle or group of muscles  Epileptic myoclonus • Typically bilaterally synchronous • Impairment of consciousness difficult to assess (seizures <1 second) • Clonic seizure – repeated myoclonic seizures (may have impaired awareness)  Differentiate from benign, nonepileptic myoclonus (e.g., while falling asleep)  EEG: Generalized 4-6 Hz polyspike-wave discharges

  17. Myoclonic Seizures

  18. Tonic and Atonic Seizures Tonic seizures • Symmetric, tonic muscle contraction of extremities with tonic flexion of waist and neck • Duration - 2-20 seconds. • EEG – Sudden attenuation with generalized, low-voltage fast activity (most common) or generalized polyspike-wave. Atonic seizures • Sudden loss of postural tone • When severe often results in falls • When milder produces head nods or jaw drops. • Consciousness usually impaired • Duration - usually seconds, rarely more than 1 minute • EEG – sudden diffuse attenuation or generalized polyspike-wave

  19. Tonic and Atonic Seizures

  20. Generalized Tonic-Clonic Seizures • Associated with loss of consciousness and post-ictal confusion/lethargy • Duration 30-120 seconds • Tonic phase • Stiffening and fall • Often associated with ictal cry • Clonic Phase • Rhythmic extremity jerking • EEG – generalized polyspikes

  21. Epilepsy Syndromes Epilepsy Syndrome Grouping of patients that share similar: • Seizure type(s) • Age of onset • Natural history/Prognosis • EEG patterns • Genetics • Response to treatment

  22. Epilepsy Syndromes

  23. Etiology of Seizures and Epilepsy  Infancy and childhood • Prenatal or birth injury • Inborn error of metabolism • Congenital malformation  Childhood and adolescence • Idiopathic/genetic syndrome • CNS infection • Trauma

  24. Etiology of Seizures and Epilepsy  Adolescence and young adult • Head trauma • Drug intoxication and withdrawal*  Older adult • Stroke • Brain tumor • Acute metabolic disturbances* • Neurodegenerative *causes of acute symptomatic seizures, not epilepsy

  25. Questions Raised by a First Seizure  Seizure or not?  Focal onset?  Evidence of interictal CNS dysfunction?  Metabolic precipitant?  Seizure type? Syndrome type?  Studies?  Start AED?

  26. Evaluation of a First Seizure • History, physical • Blood tests: CBC, electrolytes, glucose, calcium, magnesium, phosphate, hepatic and renal function • Lumbar puncture (only if meningitis or encephalitis suspected and potential for brain herniation is excluded) • Blood or urine screen for drugs • Electroencephalogram • CT or MR brain scan

  27. Seizure Precipitants  Metabolic and Electrolyte Imbalance  Stimulant/other proconvulsant intoxication  Sedative or ethanol withdrawal  Sleep deprivation  Antiepileptic medication reduction or inadequate AED treatment  Hormonal variations  Stress  Fever or systemic infection  Concussion and/or closed head injury

  28. Seizure Precipitants (cont.) Metabolic and Electrolyte Imbalance • Low blood glucose (or high glucose, esp. w/ hyperosmolar state) • Low sodium • Low calcium • Low magnesium

  29. Seizure Precipitants (cont.) Stimulants/Other Pro-convulsant Intoxication  IV drug use  Cocaine  Ephedrine  Other herbal remedies  Medication reduction

  30. EEG Abnormalities  Background abnormalities: significant asymmetries and/or degree of slowing inappropriate for clinical state or age  Interictal abnormalities associated with seizures and epilepsy • Spikes • Sharp waves • Spike-wave complexes  May be focal, lateralized, generalized

  31. Medical Treatment of First Seizure Whether to treat first seizure is controversial  16-62% will recur within 5 years  Relapse rate might be reduced by antiepileptic drug treatment  Abnormal imaging, abnormal neurological exam, abnormal EEG or family history increase relapse risk  Quality of life issues are important (ie driving) Reference: First Seizure Trial Group. Randomized Clinical Trial on the efficacy of antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic-clonic seizure. Neurology 1993; 43 (3, part1): 478-483. Reference: Camfield P, Camfield C, Dooley J, Smith E, Garner B. A randomized study of carbamazepine versus no medication after a first unprovoked seizure in childhood. Neurology 1989; 39: 851-852.

  32. Choosing Antiepileptic Drugs  Seizure type  Epilepsy syndrome  Pharmacokinetic profile  Interactions/other medical conditions  Efficacy  Expected adverse effects  Cost

  33. Choosing Antiepileptic Drugs • Limited placebo-controlled trials available, particularly of newer AEDs • In practice, several drugs are commonly used for indications other than those for which they are officially approved/recommended • Choice of AED for partial epilepsy depends largely on drug side-effect profile and patient’s preference/concerns • Choice of AED for primary generalized epilepsy depends on predominant seizure type(s) as well as drug side-effect profile and patient’s preference/concerns • ILAE and AAN recommendations indications listed in the appendix

  34. Broad-Spectrum Agents Valproate Felbamate Lamotrigine Topiramate Zonisamide Levetiracetam Rufinamide* Narrow-Spectrum Agents Partial onset seizures Phenytoin Carbamazepine Oxcarbazepine Gabapentin Pregabalin Tiagabine Lacosamide* Absence Ethosuximide Choosing Antiepileptic Drugs * New AEDs (approved 2008) categorization may change

  35. Choosing Antiepileptic Drugs (cont.) Choosing Antiepileptic Drugs (cont.) Monotherapy for Partial Seizures Best evidence and FDA indication: Carbamazepine, Oxcarbazepine, Phenytoin, Topiramate Similar efficacy, likely better tolerated: Lamotrigine, Gabapentin, Levetiracetam Also shown to be effective: Valproate, Phenobarbital, Felbamate, Lacosamide Limited data but commonly used: Zonisamide, Pregabalin Azar and Abou-Khalil, Seminars in Neurology, 2008 28:305-316

  36. Choosing Antiepileptic Drugs (cont.) Monotherapy for Generalized-Onset Tonic-Clonic Seizures Best evidence and FDA Indication: Valproate, Topiramate Also shown to be effective: Zonisamide, Levetiracetam Phenytoin, Carbamazepine (may exacerbate absence and myoclonic sz ) Lamotrigine (may exacerbate myoclonic sz of symptomatic generalized epilepsies)

  37. Choosing Antiepileptic Drugs (cont.) Absence seizures Best evidence: Ethosuximide (limited spectrum, absence only) Valproate Also shown to be effective: Lamotrigine May be considered as second-line: Zonisamide, Levetiracetam, Topiramate, Felbamate, Clonazepam

  38. Choosing Antiepileptic Drugs (cont.) Myoclonic Seizures Best evidence: Valproate Levetiracetam (FDA indication as adjunctive tx) Clonazepam (FDA indication) Possibly effective: Zonisamide, Topiramate

  39. Choosing Antiepileptic Drugs (cont.) Lennox-Gastaut Syndrome Best evidence/FDA indication*: Topiramate, Felbamate, Clonazepam, Lamotrigine, Rufinamide * FDA approval is for adjunctive treatment for all except clonazepam Also effective: Valproate Some evidence of efficacy: Zonisamide, Levetiracetam

  40. Antiepileptic Drug Monotherapy  Simplifies treatment  Reduces adverse effects  Conversion to monotherapy from polytherapy • Eliminate sedative drugs first • Withdraw antiepileptic drugs slowly over several months

  41. Antiepileptic Drug Interactions • Drugs that may induce metabolism of other drugs: • carbamazepine, phenytoin, phenobarbital, primidone • Drugs that inhibit metabolism of other drugs: • valproate, felbamate • Drugs that are highly protein bound: • valproate, phenytoin, tiagabine • carbamazepine, oxcarbazepine • topiramate is moderately protein bound • Other drugs may alter metabolism or protein binding of antiepileptic drugs (especially antibiotics, chemotherapeutic agents and antidepressants)

  42. Antiepileptic Drug Interactions Drugs that may decrease the efficacy of hormonal contraception • Phenytoin • Carbamazepine • Phenobarbital • Topiramate* • Oxcarbazepine* • Felbamate* *at high doses “High-dose” birth control pills are recommended for patients taking these medications. Lamotrigine levels decreased by hormonal contraception

  43. AED Serum Concentrations • AED serum concentrations are to be used as a guide, not dictate clinical decision making. • Serum concentrations are useful when optimizing AED therapy, assessing compliance, monitoring during pregnancy or oral contraceptive use, or teasing out drug-drug interactions. • Individual patients define their own “therapeutic” and “toxic” ranges. Patsalos PN, et al. Epilepsia.2008. 49(7): 1239-1276

  44. Adverse Effects of AEDs: Common Often dose-related: Dizziness Fatigue Ataxia Diplopia Irritability • levetiracetam Word-finding difficulty • topiramate Weight loss/anorexia • topiramate, zonisamide, felbamate Weight gain • valproate (also associated with polycystic ovarian syndrome in young women) • carbamazepine, gabapentin, pregabalin

  45. Adverse Effects of AEDs: Serious Typically idiosyncratic: Renal stones • topiramate, zonisamide Hyponatremia • carbamazepine, oxcarbazepine Aplastic anemia • felbamate, zonisamide, valproate, carbamazepine Agranulocytosis • carabamazepine Hepatic Failure • valproate, felbamate, lamotrigine, phenobarbital Anhydrosis, heat stroke • topiramate Acute closed-angle glaucoma • topiramate

  46. Adverse Effects of AEDs: Rash • 15.9% patients ever experienced a rash attributed to an AED • Average rate of AED-related rash for a given AED 2.8%, 2.1% causing AED discontinuation. • Predictors significant in multivariate analysis: • occurrence of another AED-rash Arif H et al. Neurology 2007

  47. Adverse Effects of AEDs: Rash Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TENS) • severe life threatening allergic reaction • blisters and erosions of the skin, particularly palms/soles and mucous membranes • fever and malaise • rare: severe risk roughly 1-10/10,000 for many AEDs • rapid titration of lamotrigine especially in combination with valproate increases risk

  48. Adverse Effects of AEDs: Rash Drugs rarely associated with rash • Valproate • Gabapentin • Pregabalin • Levetiracetam • Topiramate

  49. AED-related rash in adult patients with epilepsy ▲▲= rash rate significantly greater than average of all other AEDs (p<0.003) ▼▼= rash rate significantly lower than average of all other AEDs (p<0.003) ▲= trend towards significantly higher than average rash rate of all other AEDs (0.003<p<0.05) ▼= trend towards significantly lower than average rash rate of all other AEDs (0.003<p<0.05)

  50. AED-related rash in Asian patients with epilepsy FDA alert 12/2007 Risk of “dangerous or even fatal skin reactions” (SJS and TEN) are more common in those with HLA-B*1502 This allele is almost exclusively found in Asians • In 10-15% of population in China, Thailand, Malaysia, Indonesia, the Phillipines, and Taiwan • 2-4% in India • <1% in Japan and Korea 59/60 Asian patients w/ SJS/TEN had this allele vs 4% of cbz tolerant patients Estimated absolute risk for those with the allele: 5% Asians “should be screened for the HLA-B*1502 allele before starting treatment with carbamazepine” These patients may also be at risk with other AEDs • Use drugs not typically associated with rash www.fda.gov

More Related